Nkarta completes $215.5M public offering of 15.3M shares at $15/sh

Nkarta, Inc.

Sold 13.33M firm shares plus 2M option shares at $15.00/sh.
Net proceeds ~$215.5M after underwriting discounts and expenses.
Proceeds to fund NKX101, NKX019 clinical development, preclinical programs, and manufacturing.
Underwriters: Cowen, SVB Securities, Evercore.

item 8.01 item 9.01

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-006547

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.